CTI Clinical trials in lung cancer Making Cancer More Treatable
Cancer research products for clinical trials / Investigational Products / Clinical trials for lung cancer
CTI products for cancer research
Brostallicin cancer treatment for sarcoma
XYOTAX
Pixantrone cancer research drug for non-Hodgkin's lymphoma
Brostallicin cancer treatment for sarcoma
CT-2106
Clinical Studies
Clinical trials in lung cancer
Clinical trials for ovarian cancer
Clinical trial in soft tissue sarcoma
 

Lung Cancer Clinical Trials


Now enrolling for:
•

OPAXIO™ (paclitaxel poliglumex, CT-2103) in combination with carboplatin for the treatment of chemotherapy-naive advanced non-small cell lung cancer (NSCLC) in women with estradiol greater than 30 pg/mL

(OPAXIO was formerly known as XYOTAX.)


Posted May 20, 2008

Copyright © 2004-2008 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is a registered mark of CTI.